I have over 20 years of experience in neurodegenerative disease research, including 12 years with world-renowned neuropathologist Stephen J. DeArmond, M.D., Ph.D., and Nobel Laureate, Stanley Prusiner, M.D. at the University of California, San Francisco. For the last ten years, my focus has been on development of new therapeutics as part of an Alzheimer’s disease (AD) drug discovery team following a pharmaceutical industry model in an academic research setting. Our work has resulted in elevation of AD therapeutic candidate tropisetron to clinical trials. I currently supervise and perform in vivo pharmacokinetic/dynamic studies, collect and analyze all project data, and am frequently the presenter of project status to funding partners. The success of our current program, starting at the Buck Institute for Research on Aging in Novato, CA and continuing at the Mary S. Easton Center for AD Research at UCLA, has resulted in generation of multiple NCEs and garnered significant venture capital investment. In addition to writing grants and three first-author publications in the last 6 years, I give presentations at international scientific conferences such as the Alzheimer’s Association International Conference and the Society for Neuroscience Conference, and to the lay public.